Magenta Therapeutics (MGTA) IPO Opens Modestly Higher

Today's IPO for Magenta Therapeutics (NASDAQ: MGTA) opened for trading at $15.50 after pricing 6,666,667 shares of its common stock at a price to the public of $15.00 per share.

In addition, the underwriters have a 30-day option to purchase up to 1,000,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.

J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics focused on critical areas of unmet need in the field of bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases.

You May Also Be Interested In

• Rubrik, Inc. (RBRK) IPO Opens at $38.60, Priced at $32
• YY Group Holding (YYGH) Closes $5M IPO
• Massimo Group (MAMO) Expands Partnership with Global Omnichannel Retailer for Youth Series Vehicles